South San Francisco-based biotechnology company Exelixis Inc. (EXEL) said it has netted approximately $71.8 million through its public offering of 7 million shares of common stock.
Underwriter Goldman, Sachs & Co. has also been granted a 30-day option to purchase up to an additional 1.05 million shares of common stock.
‘Everywhere you turn, things that were easy are no longer easy’
‘The supply chain crisis has impacted us in almost every way imaginable’
A masterful game comes down to the bottom of the ninth, and San Francisco came up short
Some blame bureaucracy, others say it’s the residents’ fault
Climate change, social safety net among major priorities of Democrats’ 10-year funding measure
